Gengaimuthu Karthikeyan
Neonatology and Pediatrics, International Modern Hospital, Dubai, ARE.
Cureus. 2019 Aug 19;11(8):e5428. doi: 10.7759/cureus.5428.
Minimally invasive surfactant therapy (MIST) is the accepted way of surfactant administration in Europe, and in 2018, we reported its successful outcome with three babies in Dubai. Although this procedure minimizes the barotrauma associated with intubation for surfactants, threading the fine infant-feeding tube is perceived to be technically difficult. Semi-rigid catheters like the angiocath and the less invasive surfactant administration (LISA) catheter simplify the procedure. We have used successfully the smallest size of endotracheal tube available (2.0 mm) as a surrogate LISA catheter in our neonatal unit in Dubai. We present herein the simplicity and ease of this procedure versus the conventional LISA or MIST technique.
微创表面活性剂治疗(MIST)是欧洲公认的表面活性剂给药方式,2018年,我们在迪拜报告了用其成功治疗三名婴儿的案例。尽管该程序将与表面活性剂插管相关的气压伤降至最低,但插入细的婴儿喂养管在技术上被认为是困难的。像血管内导管和微创表面活性剂给药(LISA)导管这样的半刚性导管简化了该程序。在迪拜的新生儿病房,我们成功地使用了可用的最小尺寸气管内导管(2.0毫米)作为替代LISA导管。本文展示了该程序相对于传统LISA或MIST技术的简便性。